KRMD Shares Rise After Strong Q3 Revenue Growth And Raised 2025 Guidance

KORU Medical Systems (KRMD) reported robust Q3 2025 results, with revenue increasing 27% year-over-year to $10.4 million, primarily driven by strong international demand for its Freedom Syringe Infusion System and new pharmaceutical collaborations. The company significantly narrowed its net loss to $0.8 million and achieved positive adjusted EBITDA, prompting an upward revision of its full-year 2025 revenue guidance to $40.5-$41.0 million, representing 20%-22% growth, which fueled an over 8% premarket stock increase.

Analysis

KORU Medical Systems (KRMD) reported a robust Q3 2025, with total revenue increasing 27% year-over-year to $10.4 million, primarily driven by strong international demand for its Freedom Syringe Infusion System. Core business revenue, excluding non-core items, grew 30% to $9.8 million, reflecting successful adoption in strategic international markets and new patient starts. This performance indicates effective market penetration and product acceptance.

The company significantly improved its profitability metrics, narrowing its net loss to $0.8 million ($0.02 per share) from $1.6 million ($0.03 per share) in Q3 2024. Adjusted EBITDA turned positive at $0.09 million, a 121% improvement from a $0.4 million loss, signaling enhanced operational efficiency. Gross profit increased 21% to $6.3 million, though the 60.2% gross margin was impacted by higher manufacturing costs and geographic sales mix, with Q4 improvement anticipated.

Reflecting this strong operational momentum, KORU raised its full-year 2025 revenue guidance to a range of $40.5 million to $41.0 million, representing 20%-22% year-over-year growth, up from the previous $39.5 million to $40.5 million. The company also reaffirmed its 61%-63% full-year gross margin guidance and expects to conclude the year with a cash balance exceeding $8.2 million.

The positive outlook is further bolstered by two new pharmaceutical services and clinical trial collaborations, which are strategically expanding the Freedom System's reach into new patient populations. This news catalyzed an over 8% premarket stock increase, with shares trading at $4.11, demonstrating positive investor reaction to the company's financial and strategic progress.

Key Decisions for Investors

• Investors should monitor KORU's ability to sustain international demand and execute on expected Q4 gross margin improvements, as these are critical for continued profitability.
• Consider the upward revision of full-year revenue guidance and the achievement of positive Adjusted EBITDA as key indicators of improving fundamentals and market traction.
• Evaluate the long-term impact of new pharmaceutical collaborations on expanding market reach and diversifying revenue streams, which could support sustained growth beyond 2025.